Revolution Medicines, Inc. (FRA:42Z)
Germany · Delayed Price · Currency is EUR | Market Cap | 25.39B +375.3% |
| Revenue (ttm) | n/a |
| Net Income | -963.53M |
| EPS | -5.07 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 25 |
| Average Volume | 152 |
| Open | 119.20 |
| Previous Close | 122.50 |
| Day's Range | 113.95 - 122.65 |
| 52-Week Range | 29.60 - 131.95 |
| Beta | n/a |
| RSI | 68.69 |
| Earnings Date | May 7, 2026 |
About Revolution Medicines
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236)... [Read more]
News
Revolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual Meeting
REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted ...
Two experimental drugs showed striking early results against pancreatic cancer
Results from two early-stage trials offer new hope for a cancer that kills around one in eight patients within five years.
Revolution Medicines to Present Preclinical Data on Innovative Mutant-Targeted Catalytic RAS(ON) Inhibitor at the 2026 AACR Annual Meeting
Data highlight RM-055's ability to overcome resistance and provide deep, durable antitumor activity across preclinical models of pancreatic ductal adenocarcinoma, non-small cell lung cancer and colore...
Revolution Medicines to Present Pivotal Phase 3 RASolute 302 Clinical Trial Results for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer During a Plenary Session at the 2026 ASCO Annual Meeting
REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted ...
Revolution Medicines to Present Updated Phase 1 Clinical Data for Zoldonrasib in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer at the 2026 AACR Annual Meeting
REDWOOD CITY, Calif., April 19, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted ...
Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
REDWOOD CITY, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted ...
Top 2 Health Care Stocks That May Fall Off A Cliff In Q2
As of April 17, 2026, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
This Pill May Help Pancreatic Cancer Patients Live Longer
In this week's edition of InnovationRx, we look at Revolution Medicine's pancreatic cancer pill, the top self-made healthcare entrepreneurs, the latest 30 Under 30 Science & Healthcare list, and more....
Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes
REDWOOD CITY, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announ...
Revolution Medicines, Inc. Announces Proposed Offerings of Common Stock and Convertible Senior Notes
REDWOOD CITY, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announ...
Revolution Medicines surges 38% as pancreatic cancer drug shows breakthrough
Shares of Revolution Medicines surged sharply on Monday after the company reported positive results from a late-stage trial of its experimental pancreatic cancer drug, raising hopes for a potential br...
Revolution Medicines Rallies After Phase 3 Pancreatic Cancer Trial Doubles Survival Versus Chemo
The late-stage clinical oncology company is focused on developing targeted therapies for patients with RAS-addicted cancers.
Revolution Medicines' potential breakthrough pancreatic cancer drug succeeds in late-stage trial.
Revolution Medicines' drug for pancreatic cancer succeeded in a highly anticipated Phase 3 trial, almost doubling the typical length of survival and slashing the risk of death by 60% versus chemothera...
This Biotech Stock Soars 38%. Pancreatic Cancer Trial Was a Success.
Revolution Medicines announces positive Phase 3 clinical trial results for its pancreatic cancer treatment.
Revolution Medicines' experimental cancer pill helps improve survival in late-stage study
Revolution Medicines' experimental oral drug helped patients with pancreatic cancer live longer and showed an improvement in survival without worsening of the disease in a keenly anticipated late-sta...
Revolution Medicines' potential breakthrough pancreatic cancer drug succeeds in late-stage trial
Revolution Medicines says its pancreatic cancer drug daraxonrasib succeeded in a Phase 3 trial. RevMed said its drug almost doubled the typical length of survival and slashed the risk of death by 60% ...
Former Sen. Ben Sasse shines the spotlight on a possible breakthrough for pancreatic cancer
Revolution Medicines expects to soon report results from a Phase 3 trial of its daily pill daraxonrasib for pancreatic cancer. Former Republican Sen.
Revolution Medicines to Showcase Progress Across RAS(ON) Targeted Oncology Pipeline with Multiple Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting
REDWOOD CITY, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted c...
Revolution Medicines Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress
REDWOOD CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted c...
Revolution Medicines to Participate in TD Cowen 46th Annual Health Care Conference
REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted c...
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2025 After Market Close on February 25, 2026
REDWOOD CITY, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted c...
Revolution Medicines to Participate in Guggenheim Securities Emerging Outlook: Biotech Summit 2026
REDWOOD CITY, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted c...
Overlooked Stock: RVMD Sells After MRK Turns Away
Revolution Medicines (RVMD) reversed a lot of its recent rally on Monday after the Wall Street Journal reported that Merck (MRK) is no longer looking to buy the biotech firm. However, as George Tsilis...
Revolution Medicines Stock Sinks After Merck Deal Talks Collapse
Merck & Co., Inc. (NYSE: MRK) has reportedly ended discussions to acquire cancer drug developer Revolution Medicines, Inc. (NASDAQ: RVMD) after the two sides disagreed on valuation.
Merck no longer in talks to buy Revolution Medicines, WSJ reports
Merck is no longer in discussions to buy cancer drug developer Revolution Medicines , the Wall Street Journal reported on Sunday.